Direct targeting of Bcl-xL and Mcl-1 improved efficacy in CRPC cells, suggesting new treatment strategies.
Figure S2 shows the single agent activity of BH3 mimetics across LNCaP95, VCaP-CR, and 22Rv1 cells.
No takes yet. Share an insight, caveat, or question.
Brim et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: